Dr. Calais is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
200 Medical Plaza
Suite B114
Los Angeles, CA 90095Phone+1 310-825-2110Fax+1 310-825-2110- Is this information wrong?
Summary
- Assistant Professor at the Ahmanson Translational Theranostics Division of the Department of Molecular and Medical Pharmacology. Dr. Calais received his MD degree from the University of Paris-Diderot in 2010. He subsequently trained in nuclear medicine and cancer imaging at the Henri Becquerel Cancer Center of the University of Rouen and was board certified by the French Society of Nuclear Medicine in 2014. His work focuses on improving the outcomes of cancer patients by translating and applying novel diagnostic and therapeutic approaches. He uses PET/CT imaging for cancer phenotyping, radiation therapy planning and therapy response assessment. He leads the clinical research program of Nuclear Medicine and Theranostics at UCLA that combines radionuclide therapy and imaging.
Education & Training
University of Paris VII Faculty of MedicineClass of 2010
Certifications & Licensure
CA State Medical License 2020 - 2022- CA State Medical License 2020 - 2021
Clinical Trials
- Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer Start of enrollment: 2020 Aug 14
- Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy Start of enrollment: 2022 Jan 13
Roles: Contact, Principal Investigator
- Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT) Start of enrollment: 2024 Jul 01
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- [Ga]Ga-FAPI-46 False-Positive Uptake After Chemotherapy in Nonseminomatous Germ Cell Tumor Metastatic Lesions.Vinicius Ludwig, Peter George Maliha, David Tonnelet, Steve Raman, John Shen, Mark S Litwin, Jeremie Calais> ;Journal of Nuclear Medicine. 2024 Apr 25
- Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).Ethan Lam, Kiara Adame Booker, Wolfgang P Fendler, Matthias Eiber, Boris Hadaschik, Ken Herrmann, Nader Hirmas, Helena Lanzafame, Martin Stuschke, John Nikitas, Johann...> ;Journal of Nuclear Medicine. 2024 Apr 25
- RECIP 1.0 Predicts Progression-Free Survival After [Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.Loic Djaileb, Isabel Rauscher, Wolfgang P Fendler, Boris Hadaschik, Steven P Rowe, Ken Herrmann, Matthew B Rettig, Manuel Weber, Andrea Farolfi, Matthias Eiber, Andrei...> ;Journal of Nuclear Medicine. 2024 Apr 18
- Join now to see all
Press Mentions
Targeted Therapy for Early Breast Cancer and Advances in PSMA PET Scans at ASCOMay 22nd, 2023- Newly Developed PSG Score Improves Patient Selection for PSMA Radiopharmaceutical TherapyApril 20th, 2023
- Advanced Prostate Cancer Practice Informing Data Presented at ASCO 2022 - Neeraj AgarwalJanuary 5th, 2023
- Join now to see all
Hospital Affiliations
Ronald Reagan UCLA Medical CenterLos Angeles, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
